The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).
Alberto F. Sobrero
Consultant or Advisory Role - Amgen (U); Bayer (U); Merck (U); Roche (U); Sanofi (U)
Honoraria - Amgen; Merck; Roche; Sanofi
Marc Peeters
Consultant or Advisory Role - Amgen (U)
Honoraria - Amgen
Research Funding - Amgen
Timothy Jay Price
Consultant or Advisory Role - Amgen (U)
Yevhen Hotko
No relevant relationships to disclose
Andres Cervantes-Ruiperez
Consultant or Advisory Role - Amgen (U)
Michel Ducreux
Consultant or Advisory Role - Amgen (U)
Thierry Andre
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Merck
Emily Chan
Consultant or Advisory Role - Amgen (U)
Florian Lordick
Honoraria - Amgen
Ying Tian
Employment or Leadership Position - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen